MAPT and Alzheimer disease: To test if COVID-19 infection impacted AD-related protein pathologies, we quantified the burden of Aβ plaques (anti-Ab5 [49]) (Fig. 2A) and tau/NFT (anti-7F2 [50]) (Fig. 2F) in COVID, Non-COVID and Pre-2020 patients.